NASDAQ$SPRB
Spruce Biosciences Inc · Q4 2026 earnings
Q4 2026 earnings · · Before market open
Briefing
Spruce Biosciences reported fiscal Q4 2026 revenue of $0 with a net loss of $12.3M and diluted loss per share of $8.94.
For the quarter ended March 31, 2026, Spruce Biosciences had no revenue and reported a net loss of $12.3 million versus $10.5 million a year ago. Diluted loss per share was $8.94 compared with $11.20 on a much smaller prior share count after reverse splits and offerings. R&D expense was $9.1 million on tildacerfont development for congenital adrenal hyperplasia.
- No revenue; net loss of $12.3M.
- Diluted loss per share was $8.94 reflecting reverse split-adjusted share count.
- R&D spend of $9.1M on tildacerfont CAH program.
- Clinical data and regulatory path remain key value drivers.
- Cash supports ongoing trial and pre-commercial activities.
Headline financials
Revenue & EPS history
Spruce Biosciences Inc · Revenue · Quarterly
$0
Forward guidance
Spruce does not issue EPS guidance in the 10-Q and focuses MD&A on tildacerfont clinical milestones and potential partnership or financing to reach commercialization.
Tailwinds
- CAH program continues toward pivotal data readouts.
- Loss per share improved versus prior year on share-count changes.
Headwinds
- No product revenue and persistent R&D cash burn.
- Regulatory and commercial timeline uncertainty for tildacerfont.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 14 quarterly earnings reports · overlaid with Q4 2026
-1.7%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-0.6%
Avg return
30 days after
27%
4 / 15 earnings
Positive
+6.1%
Q3 2022
Best reaction
-10.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +2.1% | -9.3% | -9.5% | |
| Q3 2025 | -2.6% | -8.0% | -23.5% | |
| Q2 2025 | -5.9% | -4.2% | +33.3% | |
| Q1 2025 | -1.4% | +4.2% | -9.7% | |
| Q3 2024 | -1.3% | -7.9% | -27.4% | |
| Q2 2024 | -4.6% | +3.2% | +7.3% | |
| Q1 2024 | -3.4% | -10.0% | -20.2% | |
| Q3 2023 | +2.9% | +28.6% | +65.7% | |
| Q2 2023 | -1.6% | +5.6% | +11.9% | |
| Q1 2023 | -2.2% | +4.5% | +6.3% | |
| Q3 2022 | +6.1% | +6.1% | +3.0% | |
| Q2 2022 | +1.0% | +10.8% | -7.2% | |
| Q1 2022 | -10.5% | -6.3% | +8.4% | |
| Q3 2021 | -1.9% | -34.5% | -44.1% | |
| Q2 2021 | -2.2% | -5.2% | -3.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro